WO2002011668A3 - 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients - Google Patents

5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients Download PDF

Info

Publication number
WO2002011668A3
WO2002011668A3 PCT/KR2001/001351 KR0101351W WO0211668A3 WO 2002011668 A3 WO2002011668 A3 WO 2002011668A3 KR 0101351 W KR0101351 W KR 0101351W WO 0211668 A3 WO0211668 A3 WO 0211668A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
fluorocytosine
derivatives
deoxy
active ingredients
Prior art date
Application number
PCT/KR2001/001351
Other languages
French (fr)
Other versions
WO2002011668A2 (en
Inventor
Kwan-Hee Kim
Youn-Chul Kim
Ji-Young Kim
Kyeong-Ho Lee
Moon-Jong Noh
Young-Seok Park
Sung-Min Cho
Ho-Jin Park
Original Assignee
Kolon Inc
Kim Kwan Hee
Kim Youn Chul
Kim Ji Young
Lee Kyeong Ho
Noh Moon Jong
Park Young Seok
Cho Sung Min
Park Ho Jin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020000046179A external-priority patent/KR100730768B1/en
Priority claimed from KR1020010044193A external-priority patent/KR20030009649A/en
Application filed by Kolon Inc, Kim Kwan Hee, Kim Youn Chul, Kim Ji Young, Lee Kyeong Ho, Noh Moon Jong, Park Young Seok, Cho Sung Min, Park Ho Jin filed Critical Kolon Inc
Priority to EP01957021A priority Critical patent/EP1311524A2/en
Priority to US10/333,984 priority patent/US20030166606A1/en
Priority to JP2002517006A priority patent/JP2004505899A/en
Priority to AU2001278804A priority patent/AU2001278804A1/en
Publication of WO2002011668A2 publication Critical patent/WO2002011668A2/en
Publication of WO2002011668A3 publication Critical patent/WO2002011668A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Disclosed is a new fluorocytosine and derivatives thereof. The fluorocytosine and derivatives thereof provide a pharmaceutical composition exhibiting better anti-cancer characteristics than the conventional composition.
PCT/KR2001/001351 2000-08-09 2001-08-08 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients WO2002011668A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01957021A EP1311524A2 (en) 2000-08-09 2001-08-08 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
US10/333,984 US20030166606A1 (en) 2000-08-09 2001-08-08 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
JP2002517006A JP2004505899A (en) 2000-08-09 2001-08-08 5'-Deoxy-N- (substituted oxycarbonyl) -5-fluorocytosine and derivatives thereof, method for producing the same, and anticancer composition containing the same as an active ingredient
AU2001278804A AU2001278804A1 (en) 2000-08-09 2001-08-08 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR2000/46179 2000-08-09
KR1020000046179A KR100730768B1 (en) 2000-08-09 2000-08-09 5'-deoxy-N-alkyloxycarbonyl-5-fluorocytosine-5'-carboxylic acid and its derivatives, and process for preparing thereof
KR2001/44193 2001-07-23
KR1020010044193A KR20030009649A (en) 2001-07-23 2001-07-23 N-alkynyloxycarbonyl-5-fluorocytosine derivatives, their preparation method, and anticancer agent comprising the same

Publications (2)

Publication Number Publication Date
WO2002011668A2 WO2002011668A2 (en) 2002-02-14
WO2002011668A3 true WO2002011668A3 (en) 2002-04-18

Family

ID=26638291

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2001/001351 WO2002011668A2 (en) 2000-08-09 2001-08-08 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients

Country Status (5)

Country Link
EP (1) EP1311524A2 (en)
JP (1) JP2004505899A (en)
CN (1) CN1446225A (en)
AU (1) AU2001278804A1 (en)
WO (1) WO2002011668A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100216736A2 (en) * 2006-07-21 2010-08-26 Taiho Pharmaceutical Co., Ltd. 2'-cyanopyrimidine nucleoside compound
CN101993464B (en) * 2009-08-19 2014-07-23 成都弘达药业有限公司 Preparation method of capecitabine
CN103897004B (en) * 2012-12-27 2017-05-31 鲁南制药集团股份有限公司 A kind of synthetic method of capecitabine
JP6950972B2 (en) * 2016-06-28 2021-10-20 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ Compositions and Methods for the Treatment of Cancer
WO2018200859A1 (en) * 2017-04-26 2018-11-01 Kalman Thomas I Multitargeted nucleoside derivatives
EP3817732A4 (en) * 2018-08-03 2022-06-08 Cellix Bio Private Limited Compositions and methods for the treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814639A (en) * 1990-02-01 1998-09-29 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5852027A (en) * 1991-02-22 1998-12-22 Emory University Antiviral 1,3-dioxolane nucleoside analogues
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5814639A (en) * 1990-02-01 1998-09-29 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5852027A (en) * 1991-02-22 1998-12-22 Emory University Antiviral 1,3-dioxolane nucleoside analogues

Also Published As

Publication number Publication date
CN1446225A (en) 2003-10-01
JP2004505899A (en) 2004-02-26
EP1311524A2 (en) 2003-05-21
WO2002011668A2 (en) 2002-02-14
AU2001278804A1 (en) 2002-02-18

Similar Documents

Publication Publication Date Title
WO2001032632A3 (en) Pharmaceutically active 4-substituted pyrimidine derivatives
HUP9802822A3 (en) Halobenzimidazol derivatives, intermediates, preparation thereof and microbocide compositions containing these compounds as active ingredients
CA2326756A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
CA2358062A1 (en) Controlled release galantamine composition
AU2001237526A1 (en) Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
WO2001072728A3 (en) Novel piperazine derivatives
CA2163837A1 (en) Crystalline Paclitaxel Hydrates
CA2475113A1 (en) Isothiazole derivatives useful as anticancer agents
EP0950402A3 (en) Chewable pharmaceutical composition with gelatin matrix
CA2182582A1 (en) Compositions containing micronized nebivolol
CA2382919A1 (en) Bicyclic imidazo-3-yl-amine derivatives
CA2419314A1 (en) Preparation of risperidone
CA2360557A1 (en) Biodegradable and thermosensitive polyphosphazenes and their preparation method
AU4949800A (en) 2-arylpurine-9-acetamide derivatives, process for the preparation thereof, medicinal compositions containing the same and intermediates of the derivatives
WO2003014079A8 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
EP0990648A4 (en) 4-quinolinol derivatives and agrohorticultural bactericides containing the same as active ingredient
SI1417206T1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
AU764280C (en) Process for the preparation of pellets with a content of up to 90 wt. per cent of a pharmaceutical active ingredient
AU2001235737A1 (en) Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
EP2017269A9 (en) A pharmaceutical composition comprising form II crystalline Ritonavir and a preparation thereof
CA2412047A1 (en) Shortened synthesis of 3,3-diarylpropylamine derivatives
HUP9901616A3 (en) Novel benzofuranone derivatives, process for their production and pharmaceutical compositions of the same
HUP9900365A3 (en) N-aryl-1,2,4-triazolin-5-on derivatives, preparation and use thereof, insecticide, arachnicide and nematocide compositions containing these compounds as active ingredients
WO2002032901A3 (en) Bridged piperazine derivatives
CA2337667A1 (en) Dextran-leptin conjugates, pharmaceutical compositions and related methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10333984

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001957021

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018137415

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002517006

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001957021

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001957021

Country of ref document: EP